In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DuPont Merck's Coumadin

Executive Summary

Anticoagulant warfarin receives additional indication for prevention and treatment of thromboembolic complications associated with cardiac valve replacements. Coumadin is already widely used for preventing blood clots in patients with artificial heart valves, the company notes April 25; published data indicate that long-term Coumadin therapy reduces the number of thromboembolic events in patients with heart valve replacements to less than 3%, compared to 22% in untreated patients. FDA granted the supplemental approval March 31



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts